CHAPEL HILL, N.C., April 4, 2008 /PRNewswire/ -- Companies align commercial and portfolio management employees by therapeutic area. For a company with an annual sales volume of $10 to 20 billion, on average nine marketing FTEs are assigned to the early-stage commercialization team along with approximately eight portfolio managers. At companies with smaller sales volumes, the ratio is approximately four to three, commercial to portfolio management staff, according to a study by pharmaceutical benchmarking firm Best Practices, LLC.
In light of a changing industry with heightened focus on research and development, pharmaceutical companies are now significantly increasing resources to support for early-stage commercialization.
The benchmarking report, "Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence," available with a complimentary study summary online at http://www3.best-in-class.com/rr924.htm, provides extensive insight into how pharmaceutical, biotech and medical device companies are preparing their newest employees for the competitive marketplace in which they are being asked to excel.
Best Practices, LLC gathered valuable best practices and operating tactics from leading pharmaceutical companies, including Amgen, Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi-Aventis and Wyeth. They will help executives build and manage strong teams that can excel across functions, units and regions.
Cross-function collaboration is greatly improved through many methods,
including structuring jobs with overlapping responsibilities, basing
rewards on group performance, designing procedures so that employees with
different jobs are better able to collaborate, and laying out work areas so
that people can see
|SOURCE Best Practices, LLC|
Copyright©2008 PR Newswire.
All rights reserved